Neonatal outcomes of pregnancy complicated by idiopathic thrombocytopenic purpura

J Perinatol. 2010 Jan;30(1):38-44. doi: 10.1038/jp.2009.134. Epub 2009 Sep 24.

Abstract

Objective: The aim of this study was to determine the factors associated with the prognosis of newborns born to mothers with idiopathic thrombocytopenic purpura (ITP), and to compare the infants with/without thrombocytopenia in terms of maternal and neonatal characteristics.

Study design: We reviewed the charts of 29 parturients with ITP and their newborns who were born between January 1998 and December 2008.

Result: A total of 16 (55%) gravidas had been diagnosed with ITP before pregnancy and 13 (45%) were diagnosed during pregnancy. Thrombocytopenia was observed in 21 gravidas. In total, 17 (58%) gravidas received treatment to increase the platelet count. The majority of deliveries (72.5%) were vaginal. The infant platelet counts at birth ranged from 20 to 336 x 10(9) per liter. None of the neonates had complications attributable to the mode of delivery. Normal platelet counts were determined in 15 newborns, whereas 14 infants had thrombocytopenia at birth. Three (10.3%) neonates had mild, four neonates (13.7%) had moderate and seven neonates (24.1%) had severe thrombocytopenia. The age of the mothers having infants with thrombocytopenia was significantly higher (30+/-5.3 vs 25.3+/-3.8 years), most of the infants (10/14 (71%)) were males (P<0.05).

Conclusion: Pregnancy complicated with ITP generally has a good outcome. Although ITP in pregnancy carries a low risk, careful observation is required for the newborn of gravidas with ITP even when the infant has no bleeding complications at delivery, and infants may require treatment for thrombocytopenia.

MeSH terms

  • Adult
  • Female
  • Gestational Age
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant, Newborn
  • Male
  • Platelet Count
  • Pregnancy
  • Pregnancy Complications, Hematologic*
  • Purpura, Thrombocytopenic, Idiopathic / complications*
  • Retrospective Studies
  • Risk Factors
  • Sex Factors
  • Thrombocytopenia, Neonatal Alloimmune / etiology*
  • Thrombocytopenia, Neonatal Alloimmune / therapy
  • Young Adult

Substances

  • Immunoglobulins, Intravenous